UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review
June 07, 2013 at 12:31 PM EDT
In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ ), but lowered the price target from $97.00 to $91.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in
